GlycoMimetics

📍 Rockville, United States🗓 Founded 2003👥 50 employees💰 Last funded Jan 2003
Pharmaceutical Manufacturing🌐 glycomimetics.com
Website LinkedIn
At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. We are a public company traded on the NASDAQ under the symbol GLYC.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2003
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in GlycoMimetics?
GlycoMimetics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did GlycoMimetics last raise funding?
The most recent investment in GlycoMimetics recorded on gritt.io was in January 2003.
When was GlycoMimetics founded?
GlycoMimetics was founded in 2003.
What industry is GlycoMimetics in?
GlycoMimetics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is GlycoMimetics based?
GlycoMimetics is headquartered in Rockville, United States.